-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 21st, The Company announced that it had recently received a Notice of Approval of Drug Supplemental Application for Misoprostol Tablets approved by the State Drug Administration, and that the Company's Misoprostol Tablets had been evaluated by the quality and efficacy of generic drugs.
misoprostol, a prostatin E1 similar, was researched and developed by Searle (now Pfizer) in 1973 and its tablets were first licensed for sale in 1984 under the trade names Cytotec, available in 0.1mg and 0.2mg sizes.
because of its uterine contractions, it has been widely used in pregnancy and pregnant women's various adaptive disorders, such as drug abortion, cervical maturation, pre-surgery softening of the cervix and so on.
the domestic approved adaptations are: combined with the methadone tablet sequence, which can be used to terminate an in-house pregnancy of up to 16 weeks (112 days), including: (1) for the termination of a pregnancy within 7 weeks (49 days) and (2) for the termination of a pregnancy within 8 to 16 weeks (50 to 112 days).
